Clinical Data Psyched For Vilazodone NDA Filing In Second Half
This article was originally published in The Pink Sheet Daily
Executive Summary
Company anticipates data from a second Phase III trial evaluating the SSRI/5HT1A partial agonist for depression in the second quarter.